ClinicalTrials.gg
RecruitingNCT07807839Updated Sep 8, 2026

Study of Correlation Between Serum BDNF Levels and Pfirmann Grading and IL- 1β

An observational study in Chronic Low Back Pain (CLBP), sponsored by Keimyung University Dongsan Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Keimyung University Dongsan Medical Center · Observational

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
59
Ages
20 Years to 80 Years
Sex
All
01

Study summary

Brain-derived neurotrophic factor (BDNF) is a protein belonging to the neurotrophin family, known to be involved in neuronal survival, growth, and synaptic plasticity. Recent studies suggest that the role of BDNF may extend beyond the central nervous system to include inflammatory responses and degenerative changes in peripheral tissues. In particular, BDNF expression has been confirmed within intervertebral disc tissue, with degenerated discs showing increased BDNF expression compared to normal discs, and this expression has been reported to increase further with the severity of degeneration Intervertebral disc degeneration is closely associated with intradiscal nerve ingrowth (neoinnervation) and the resulting generation of pain, and BDNF has been reported as a factor mediating this nerve ingrowth and pain sensitization (central/peripheral sensitization) within the disc. Interleukin-1 beta (IL-1β), a representative inflammatory cytokine of disc degeneration, is known as a key mediator that promotes extracellular matrix degradation within disc tissue and induces neoinnervation and sensitization. Because BDNF secretion from neurons and immune cells has also been reported to increase in inflammatory environments, a potential interaction between IL-1β and BDNF has been proposed Accordingly, this study aims to measure serum BDNF concentrations in patients presenting with low back and leg pain due to disc degeneration or spinal stenosis, and to analyze whether these levels show a consistent correlation with Pfirrmann grading on MRI and serum IL-1β concentration.

02

Conditions studied

  • Chronic Low Back Pain (CLBP)

Browse trials for

Keywords

  • low back pain
  • serum BDNF
03

In context

Low Back Pain

2,922 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.

This study's planned enrollment of 59 is below the median of 100 across 481 observational studies indexed under Low Back Pain.

Browse Low Back Pain studies →

Lead sponsor

Keimyung University Dongsan Medical Center is the lead sponsor of 86 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

low back pain population with disc degeneration confirmed in MRI

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • lumbar disc herniation
  • lumbar spinal canal stenosis
  • patients who have MRI

Exclusion criteria

Exclusion Criteria:

  • spine fracture
  • spine infection
  • spine tumor
  • rhematoid arthritis
  • ankylosing spondylitis
  • systemic lupus erythematosus
  • peripheral neuropathy
  • fibromyalgia
  • patient taking antidepressant, antipsychotics, acetylcholiesterase inhibitor
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
59 participants (estimated)
Patient registry
No

Groups and cohorts

  • back pain patient group

    Procedure: blood sampling for ELISA

Interventions

  • Procedureblood sampling for ELISA

    blood sampling to detect the level of BDNF

06

What researchers measure

Primary outcomes

  1. Idenfifying the correlation of BDNF level and Pfirmann grading

    Time frame: day 1

Secondary outcomes

  1. Idnetifying the correlation of BDNF level and IL-1β

    Time frame: day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.

Of 175 non-industry observational studies under Low Back Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 11 months is below that.

Counting every sponsor, half of 185 studies reached it within 24 months; a quarter within 10 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Sep 8, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Aug 30, 2027
CompletionEst.
Aug 30, 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07807839
Lead sponsor
Keimyung University Dongsan Medical Center
Responsible party
Ji Hee Hong (professor, Keimyung University Dongsan Medical Center) — Principal investigator
First posted
Sep 8, 2026
Start date
Sep 1, 2026
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

JIHEE Hong
Contact
swon13@daum.net
01046794343

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion